OxSyBio

HardwareLondon, United Kingdom (in liquidation; prior ops Harwell Campus, Oxfordshire)Founded 2014· One of 1818 Hardware companies tracked by AMPulse

Develops droplet-based 3D bioprinting technology to produce synthetic tissue-like materials for regenerative medicine, wound healing, and drug delivery applications.

CEO / Founder: Hadrian Green (former; resigned Feb 2019)
Team Size: 1-10
Stage: Defunct
Total Funding: $16.4M
Latest Round: Series A
Key Investors: Woodford Investment Management; IP Group; Parkwalk Advisors

Technology & Products

Key Products

3D bioprinted synthetic tissues for regenerative medicine, drug screening, and wound healing applications.

Technological Advantage

University of Oxford spin-out with foundational IP from Professor Hagan Bayley's lab; technology enables printing of functional synthetic tissues with potential for personalized treatments.

Differentiation

Value Proposition

Enables high-throughput, reproducible production of 3D printed tissues for disease modeling, drug screening, and potential organ repair, reducing reliance on donor organs and animal testing.

How They Differentiate

OxSyBio differentiates itself through its proprietary droplet-based inkjet bioprinting technology, which allows for high-throughput and reproducible production of synthetic tissue-like materials. This method offers greater precision and control compared to other bioprinting techniques, backed by its strong research ties to Oxford University.

Market & Competition

Target Customers

Medical research institutions, pharmaceutical companies, healthcare providers

Industry Verticals

Medical Research; Pharmaceuticals; Healthcare

Competitors

Organovo, CELLINK, Aspect Biosystems

Growth & Milestones

Growth Metrics

Oxford University spin-out (2014) with ~£1M seed; £10M Series A (2018). Filed micro-entity accounts (last YE 31 Dec 2020). Entered members' voluntary liquidation Mar 2022. No public evidence of £36.2M revenue (incompatible with micro accounts and pre-liquidation wind-down).

Major Milestones

Founded 2014 as Oxford University spin-out; ~£1M seed 2014; £10M Series A 2018; MRC Harwell partnership ~2018; Hadrian Green resigned as director 18 Feb 2019; members' voluntary liquidation commenced 11 Mar 2022 (ongoing through 2026).

https://www.oxsybio.com

Why this company matters

AMPulse analysis, not a company disclosure

OxSyBio is a University of Oxford spin-out developing a droplet-based 3D bioprinting platform that produces synthetic tissue-like materials. The company's technology uses artificial cells with protein pores to mimic natural tissue behavior, enabling high-resolution assembly of biological building blocks. This approach targets applications in regenerative medicine, wound healing, and drug delivery, offering an alternative to donor tissue and animal testing.

The core technology is a material jetting (MJT) bioprinting process that deposits droplets containing synthetic cells into precise three-dimensional structures. This method is designed for high-throughput and reproducible production, which is critical for disease modeling and drug screening workflows. The intellectual property originates from Professor Hagan Bayley's lab at Oxford, providing a foundation in synthetic biology and droplet microfluidics.

OxSyBio's target customers include medical research institutions, pharmaceutical companies, and healthcare providers. The company has partnered with MRC Harwell for diabetes and obesity research, indicating a focus on metabolic disease modeling. Its synthetic tissues are positioned for both research use—reducing reliance on animal models—and eventual therapeutic applications in organ repair.

The company competes with Organovo, CELLINK, and Aspect Biosystems in the bioprinting space. Its differentiation lies in the droplet-based inkjet approach, which offers precision and control distinct from extrusion or laser-based methods. A key open question is whether the synthetic tissue constructs can achieve the vascularization and long-term viability required for in vivo implantation, a challenge common across the bioprinting field.